Skip to content
Back to catalogue
NAD+ pen, black
NAD+ pen, pink

Energy & anti-ageing

NAD+

The cell-energy recharge

Format

Add a refill for your pen

NAD+ 500 mg · +AED 835 each

0

Quantity — buy more, save more

Other quantity

1

Any mix counts: items from other products add up too.

PriceAED 880

Frequently paired with

Tap Add — each one counts toward your bundle saving.

MOTS-c 40 mg

AED 1180

Semax 10 mg

AED 590

Also in a bundle: Energy & longevity

Add another item from the catalogue

Pens are added as the reusable pen; change the format on the product page if you prefer.

The coenzyme every cell uses to make energy, with levels that decline with age. Studied in cellular-energy, DNA-repair and healthy-ageing research.

Research use only. Supplied for laboratory and analytical research. Not a medicine or supplement, and not for human or animal use. We don't give dosing or clinical advice. Read the terms

Presentation
Lyophilised powder, reconstituted — 3 mL pen

Manufactured under controlled research-grade conditions. For documentation or questions about this compound, contact us on WhatsApp.

Published research

  1. Human trial

    In a 60-day randomised, placebo-controlled trial of 80 healthy middle-aged adults, oral NMN, an NAD+ precursor, raised blood NAD concentrations and increased six-minute walking distance versus placebo, and was well tolerated.

    Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023. PMID 36482258

  2. Human trial

    In a randomised, placebo-controlled crossover trial in healthy middle-aged and older adults, the NAD+ precursor nicotinamide riboside was well tolerated and increased NAD+ metabolism.

    Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nature Communications. 2018. PMID 29599478

  3. Human trial

    In a randomised, placebo-controlled trial in healthy older men, 6–12 weeks of oral NMN, an NAD+ precursor, raised whole-blood NAD+ and its metabolites; gait speed and left grip strength improved only nominally, and body composition did not change.

    Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj Aging. 2022. PMID 35927255

  4. Human trial

    In a placebo-controlled crossover trial of 22 healthy older adults, 6 weeks of oral nicotinamide riboside, an NAD+ precursor, raised NAD+ in plasma vesicles enriched for neuronal origin and lowered their levels of Aβ42, pJNK and pERK1/2.

    Vreones M, et al. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. 2023. PMID 36515353

  5. Human trial

    In a one-person pilot and a first human pharmacokinetic trial, single oral doses of nicotinamide riboside, an NAD+ precursor, raised blood NAD+ metabolites dose-dependently; in mice, oral nicotinamide riboside raised liver NAD+.

    Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. 2016. PMID 27721479

Short summaries of published studies, with links to the original papers. Results in animals or cells may not apply to people. This is not medical advice and not a guide to use.

All research on NAD+